Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 07/18/2025 | CALL | $50.00 | 95,947 | +3,948 | +4.29% |
| 08/15/2025 | CALL | $50.00 | 14,834 | +373 | +2.58% |
| 05/16/2025 | PUT | $46.00 | 609 | +30 | +5.18% |
| 05/16/2025 | CALL | $50.00 | 12,854 | +10 | +0.08% |
| 06/18/2026 | CALL | $50.00 | 421 | +2 | +0.48% |
| 05/16/2025 | CALL | $46.00 | 4,703 | +1 | +0.02% |
| 01/15/2027 | PUT | $60.00 | 0 | 0 | |
| 01/15/2027 | PUT | $65.00 | 0 | 0 | |
| 01/15/2027 | PUT | $70.00 | 0 | 0 | |
| 05/16/2025 | PUT | $45.00 | 2,280 | -1 | -0.04% |
| 06/20/2025 | CALL | $50.00 | 14,218 | -8 | -0.06% |
| 05/16/2025 | PUT | $40.00 | 3,564 | -28 | -0.78% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 4.36% | 2.72M | 76.14M |
| Fidelity Growth Company Fund | 4.20% | 2.63M | 73.44M |
| Vanguard Total Stock Market Index Fund | 2.33% | 1.46M | 40.78M |
| Vanguard Small-Cap Index Fund | 1.93% | 1.21M | 33.7M |
| iShares Russell 2000 ETF | 1.27% | 793.44k | 22.18M |
| Fidelity Series Growth Company Fund | 1.24% | 777.87k | 21.74M |
| Fidelity Growth Company K6 Fund | 1.21% | 758.92k | 21.21M |
| Vanguard Explorer Fund, Inc. | 1.13% | 704.12k | 19.68M |
| Vanguard Small-Cap Growth Index Fund | 1.11% | 694.23k | 19.4M |
| Vanguard Extended Market Index Fund | 0.93% | 583.42k | 16.31M |
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
04/28 12:17 pm
Benzinga
Read moreSpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
04/27 10:35 am
GlobeNewswire Inc.
Read moreOnco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics
02/17 05:05 pm
GlobeNewswire Inc.
Read moreUPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
02/11 09:20 pm
GlobeNewswire Inc.
Read moreGermany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics
02/11 12:41 pm
Benzinga
Read moreComprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight
12/19 02:00 pm
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
11/26 08:00 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
11/05 08:00 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
10/22 07:00 am
GlobeNewswire Inc.
Read moreSpringWorks (SWTX) Completes NDA Submission for Mirdametinib
07/02 12:12 pm
Zacks Investment Research
Read moreSpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
07/01 06:30 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
06/05 07:00 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
05/23 05:13 pm
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
05/08 07:00 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates
05/02 07:45 am
Zacks Investment Research
Read moreSpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
05/02 06:30 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
04/24 01:31 pm
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
04/18 07:00 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
03/04 07:30 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
02/27 07:30 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics to Present at Upcoming Investor Conferences
02/22 08:00 am
GlobeNewswire Inc.
Read moreImmunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
02/07 09:34 am
Zacks Investment Research
Read moreSpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/31 08:00 am
GlobeNewswire Inc.
Read moreSpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
01/25 10:19 am
Zacks Investment Research
Read moreSpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
01/08 07:30 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/21 08:00 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
12/05 01:32 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
12/04 05:13 pm
GlobeNewswire Inc.
Read moreLa-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday
11/30 11:12 am
Benzinga
Read moreSpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug
11/29 11:20 am
Zacks Investment Research
Read moreAnalyst Ratings for SpringWorks Therapeutics
11/29 09:00 am
Benzinga
Read moreSpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
11/29 08:00 am
GlobeNewswire Inc.
Read moreSpringWorks stock on track for record gain after FDA approves first treatment for rare type of aggressive tumors
11/28 12:06 pm
MarketWatch
Read morePDD Posts Upbeat Revenue, Joins Avidity Biosciences, SpringWorks Therapeutics And Other Big Stocks Moving Higher On Tuesday
11/28 10:39 am
Benzinga
Read moreSpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
11/27 07:04 pm
GlobeNewswire Inc.
Read moreHC Wainwright & Co. Maintains Buy Rating for SpringWorks Therapeutics: Here's What You Need To Know
11/20 01:00 pm
Benzinga
Read moreSpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data
11/17 09:40 am
Zacks Investment Research
Read moreSpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
11/16 07:30 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
11/02 06:30 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
11/01 06:30 am
GlobeNewswire Inc.
Read moreSpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
09/11 06:30 am
GlobeNewswire Inc.
Read moreSpringWorks' Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA Update
08/24 02:35 pm
Benzinga
Read moreAnalyst Ratings for SpringWorks Therapeutics
08/24 08:00 am
Benzinga
Read moreSpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
08/02 06:30 am
GlobeNewswire Inc.
Read moreAnalyst Ratings for SpringWorks Therapeutics
07/20 04:00 pm
Benzinga
Read more